Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
J Liposome Res. 2009;19(4):310-21. doi: 10.3109/08982100902913204.
Cancer continues to be a major cause of morbidity and mortality worldwide. While discovery of new drugs and cancer chemotherapy opened a new era for the treatment of tumors, optimized concentration of drug at the target site is only possible at the expense of severe side effects. Nanoscale carrier systems have the potential to limit drug toxicity and achieve tumor localization. When linked with tumor-targeting moieties, such as tumor-specific ligands or monoclonal antibodies, the nanocarriers can be used to target cancer-specific receptors, tumor antigens, and tumor vasculatures with high affinity and precision. This article is an overview of advances and prospects in the applications of nanocarrier technology in cancer therapy. Applications of nanoliposomes, dendrimers, and nanoparticles in cancer therapy are explained, along with their preparation methods and targeting strategies.
癌症仍然是全世界发病率和死亡率的主要原因。虽然新药物和癌症化疗的发现为肿瘤治疗开辟了一个新时代，但只有以严重的副作用为代价，才能使药物在靶部位达到最佳浓度。纳米载体系统有可能限制药物毒性并实现肿瘤定位。当与肿瘤靶向部分（如肿瘤特异性配体或单克隆抗体）结合时，纳米载体可用于以高亲和力和精度靶向癌症特异性受体、肿瘤抗原和肿瘤血管。本文概述了纳米载体技术在癌症治疗中的应用的进展和前景。解释了纳米脂质体、树枝状大分子和纳米粒子在癌症治疗中的应用，以及它们的制备方法和靶向策略。
